Tests tirzepatide to see if it slows kidney growth in polycystic kidney disease
Tests tirzepatide against placebo in adults with polycystic kidney disease and obesity.
Key facts
- Who runs it
- University of Colorado, Denver
- Where
- Aurora, United StatesSee the site
- Trial code
- Registry title
- Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 126 people, planned
- Started
- 6 Mar 2025
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Tirzepatide
- Placebo
- Record updated
- 6 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with autosomal dominant polycystic kidney disease (ADPKD) who are overweight or obese. It tests whether a year of treatment with a GLP-1 receptor agonist can slow kidney growth.
- Age
- 18-65 years
- Sex
- All sexes can join.
- Disease stage
- ADPKD diagnosed by the modified Pei-Ravine criteria. Mayo Classification of C, D, or E, from a kidney ultrasound or MRI done in the last 12 months. Estimated glomerular filtration rate ≥ 30 mL/min/1.73m^2.
- Earlier treatment
- People cannot join if they use tolvaptan or plan to start it. They also cannot join if they take regular medicines that may affect weight, appetite, food intake, or energy metabolism.
- Biomarker or test result
- Body-mass index of ≥27 kg/m^2.
Main reasons for not taking part
- Diabetes mellitus
- Tolvaptan use or plans to start tolvaptan
- Pregnancy, breastfeeding, or unwillingness to use adequate birth control
- Uncontrolled high blood pressure (systolic > 160 or diastolic > 100 mm Hg)
- Personal or family history of medullary thyroid carcinoma, thyroid nodule, or multiple endocrine neoplasia type 2, or prior pancreatitis
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- 18-65 years of age
- ADPKD diagnosis based on the modified Pei-Ravine criteria
- Body-mass index of ≥27 kg/m\^2
- Estimated glomerular filtration rate ≥ 30 mL/min/1.73m\^2
- Mayo Classification of C, D, or E, calculated from a previous kidney ultrasound or MRI performed within the last 12 months
- Not currently participating in or planning to participate in any formal weight loss or physical activity program, or another interventional study
- Ability to provide informed consent
Who cannot take part
- Regular use of prescription or over-the-counter medications that may affect weight, appetite, food intake, or energy metabolism
- Inability to cooperate with or clinical contraindication for MRI including: severe claustrophobia, implants, devices, or non-removable body piercings
- Prior history of pancreatitis
- Diabetes mellitus
- History of hospitalization or major surgery within the last 3 months
- Uncontrolled hypertension (systolic blood pressure > 160 or diastolic blood pressure >100 mm Hg)
- History of clinically diagnosed eating disorder including: anorexia nervosa, bulimia, binge eating disorder
- Presence or personal history of malignant neoplasm within 5 years prior to the day of screening
- Personal or family history of medullary thyroid carcinoma, thyroid nodule, or multiple endocrine neoplasia type 2
- Tolvaptan usage or plans to initiate tolvaptan
- Pregnancy, lactation, or unwillingness to use adequate birth control
- Weight change of >5% in the past 3 months for any reason except post-partum weight loss
- Weight ≥450 lb
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- University of Colorado Anschutz Medical CampusAurora, United StatesContact: Kristen Nowak, PhD, MPHTaking people
About the trial
What the trial wants to find out
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight into biological changes that may be linked to the benefits of the intervention, while ensuring careful monitoring of safety and tolerability.
The 2 groups in the trial
- TirzepatideTreatment being tested
To minimize the risk of gastrointestinal adverse events, we will use a standard dose-escalation regimen for tirzepatide (placebo-matched), starting at 2.5 mg once weekly (OW) at randomization. After 4 weeks of treatment at 2.5 mg, the dose will be escalated to 5 mg OW, which will be maintained for another 4 weeks and then continued as the target dose for 10 months until the end of treatment. As with other nutrient stimulating hormone (NuSH) therapies, dose reductions and extensions of dose-escalation intervals will be permitted if participants experience unacceptable adverse events. The minimum tolerated dose required for continued study participation is 2.5 mg/week. All dose changes will be documented in the study records.
- PlaceboPlacebo, for comparison
To minimize the risk of gastrointestinal adverse events, we will use a standard dose-escalation regimen for tirzepatide (placebo-matched), starting at 2.5 mg once weekly (OW) at randomization. After 4 weeks of treatment at 2.5 mg, the dose will be escalated to 5 mg OW, which will be maintained for another 4 weeks and then continued as the target dose for 10 months until the end of treatment. As with other nutrient stimulating hormone (NuSH) therapies, dose reductions and extensions of dose-escalation intervals will be permitted if participants experience unacceptable adverse events. The minimum tolerated dose required for continued study participation is 2.5 mg/week. All dose changes will be documented in the study records.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Advancing ADPKD Treatment With GLP-1RA: A Study of Glucagon-Like Peptide-1 Receptor Agonists' Efficacy, Safety, and Mechanism
- Plain-language title
- Tests tirzepatide to see if it slows kidney growth in polycystic kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06582875, who can take part
- Publications
- Cardiovascular-Kidney-Metabolic Syndrome in Autosomal Dominant Polycystic Kidney Disease.Journal of the American Society of Nephrology : JASN, 2026
- Emerging Therapies in Autosomal Dominant Polycystic Kidney Disease.Kidney360, 2026
- The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care.Clinical journal of the American Society of Nephrology : CJASN, 2026
- Record updated
- 6 May 2025